Schuster Bruce Catherine, Rull Gurvinder, Sotiris Antoniou, Lobo Melvin D
Barts BP Centre of Excellence, William Harvey Research Institute, London, UK.
NIHR Barts Cardiovascular Biomedical Research Centre, London, UK.
BMJ Case Rep. 2018 Dec 13;11(1):e226045. doi: 10.1136/bcr-2018-226045.
A 61-year-old man with a 30-year history of uncontrolled hypertension was unable to tolerate conventional antihypertensive medications from all classes. At the time of referral to our centre he had discontinued all antihypertensive drugs and felt well. However, his average home blood pressure (HBP) reading was 179/125 mm Hg and echocardiography demonstrated moderate concentric left ventricular hypertrophy. A novel stratified medicines algorithm was used to guide treatment entailing transdermal clonidine patch therapy instead of tablet formulations. Sixteen months later, his average HBP was 147/106 mm Hg with no side effects and the left ventricular hypertrophy had completely regressed. Our experience has taught us that multiple drug intolerance is a common, often overlooked, cause of non-adherence to antihypertensive medication. This case demonstrates the benefit of a novel approach to optimise blood pressure control and emphasises the important role of hypertension specialists in managing complex, high-risk patients unable to tolerate guideline-based therapy.
一名有30年高血压控制不佳病史的61岁男性无法耐受所有类别的传统抗高血压药物。在转诊到我们中心时,他已停用所有抗高血压药物,感觉良好。然而,他在家中的平均血压读数为179/125 mmHg,超声心动图显示左心室中度向心性肥厚。采用一种新型分层药物算法来指导治疗,采用透皮可乐定贴片疗法而非片剂剂型。16个月后,他的平均血压为147/106 mmHg,无副作用,左心室肥厚已完全消退。我们的经验告诉我们,多种药物不耐受是抗高血压药物治疗依从性差的常见且常被忽视的原因。本病例证明了一种优化血压控制的新方法的益处,并强调了高血压专科医生在管理无法耐受基于指南治疗的复杂高危患者中的重要作用。